- Service Name
CRISPR Therapeutics
- Industry
Biotechnology, Gene Editing, Therapeutics, CRISPR Technology
- Main Value Proposition
Transforming the lives of patients living with serious diseases through innovative gene-based medicines.
- Description
CRISPR Therapeutics is dedicated to developing transformative medicines utilizing its proprietary CRISPR/Cas9 gene-editing technology. The company focuses on creating innovative therapies for serious diseases, including sickle cell disease and beta thalassemia.
- Key Features
First-ever approved CRISPR-based therapy (CASGEVY™); Diverse portfolio across multiple disease areas; Commitment to patient advocacy and community involvement; Rapid translation of revolutionary technology into therapies
- Use Cases
The service is most valuable in treating genetic disorders such as sickle cell disease, developing cell therapies for cancer, and expanding applications of stem cells through gene editing.
- Competitive advantages
Proprietary CRISPR/Cas9 gene-editing platform; Established partnerships with leading pharmaceutical companies like Vertex Pharmaceuticals; Strong focus on patient advocacy and community engagement
- Strengths
The company has a strong pipeline of therapies, a commitment to innovation, and a focus on serious diseases, which positions it as a leader in the gene-editing space.
- Positioning
CRISPR Therapeutics positions itself as a leader in gene editing, focusing on the development of transformative therapies for serious diseases.
- Audience
The target users include patients with serious genetic diseases, healthcare providers, and investors interested in innovative biopharmaceutical solutions.
- CTA
Learn more about our programs
- Tags
Gene Editing
CRISPR Technology
Therapeutics
Patient Advocacy
- Tagline
Pioneering a new era of medicines
- Tone of Voice
Innovative, compassionate, authoritative
- Differentiation
CRISPR Therapeutics stands out in the market by being a pioneer in CRISPR technology and having the first approved CRISPR-based therapy.
- Brand Positioning
The brand identity emphasizes innovation, patient commitment, and leadership in the CRISPR technology space.
- Founded
2013-01-01
- Founders
Daniel Anderson
Emmanuelle Charpentier
Matthew Porteus
Rodger Novak
Shaun Foy